Taiwan Stock Exchange · Consumer Defensive
Taiyen Biotech stock from India: price, numbers and tax
Taiyen Biotech (1737) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Taiyen Biotech at a glance
- Price
- NT$30.00+NT$0.05 (0.17%)
- Market cap
- NT$6.00B
- Day range
- NT$29.95 – NT$30.05
- P/E
- 15.38
- Dividend yield
- 4.67%
- Volume
- 76.21K
- 1 month
- -2.28%
- 6 months
- -6.25%
- YTD
- -5.36%
- 1 year
- -6.40%
- 5 years
- -11.24%
Taiyen Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$3.3B | NT$3.2B | NT$3.4B | NT$3.6B | NT$4.1B |
| Gross profit | NT$1.3B | NT$1.3B | NT$1.2B | NT$1.3B | NT$1.4B |
| Operating income | NT$476.1M | NT$430.8M | NT$312.7M | NT$535.1M | NT$515.9M |
| Net income | NT$399.9M | NT$371.5M | NT$300.4M | NT$426.7M | NT$393.2M |
| Earnings per share | NT$2.00 | NT$1.86 | NT$1.50 | NT$2.13 | NT$1.97 |
| EBITDA | NT$720.1M | NT$658.0M | NT$530.5M | NT$640.0M | NT$718.8M |
| Total assets | NT$8.3B | NT$8.4B | NT$8.3B | NT$8.2B | NT$8.5B |
| Total debt | NT$223.2M | NT$311.5M | NT$317.2M | NT$268.4M | NT$506.5M |
| Cash and short-term investments | NT$1.7B | NT$1.9B | NT$1.8B | NT$1.9B | NT$2.1B |
| Shareholders' equity | NT$6.8B | NT$6.7B | NT$6.5B | NT$6.5B | NT$6.4B |
| Operating cash flow | NT$473.8M | NT$660.1M | NT$454.5M | NT$580.7M | NT$600.1M |
| Free cash flow | NT$173.6M | NT$352.5M | NT$109.4M | NT$334.1M | NT$209.3M |
| Capital expenditure | −NT$300.2M | −NT$307.6M | −NT$341.6M | −NT$246.6M | −NT$390.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Yuen Foong Yu Consumer Products | 6790.TW | NT$37.25 | NT$9.95B |
| Chlitina | 4137.TW | NT$77.20 | NT$6.37B |
| Sunjuice | 1256.TW | NT$167.50 | NT$5.99B |
| Wei Chuan Foods | 1201.TW | NT$11.55 | NT$5.85B |
| Formosa Oilseed Processing | 1225.TW | NT$24.00 | NT$5.81B |
| Dr. Wu Skincare | 6523.TWO | $88.90 | $4.00B |
| Shiny Brands | 6703.TWO | $99.90 | $3.59B |
| Farcent Enterprise | 1730.TW | NT$51.30 | NT$3.24B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Taiyen Biotech from India
What Taiyen Biotech does
Established in 1952 and headquartered in Tainan, Taiwan, Taiyen Biotech Co., Ltd. is a multifaceted enterprise engaged in the global production and distribution of salt-based goods. The company offers a wide-ranging portfolio that includes various salt and seawater-derived chemical products, alongside an array of personal care items such as bath salts, specialty soaps, and shampoos. Taiyen Biotech operates in the Household & Personal Products industry within the Consumer Defensive sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Taiyen Biotech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.